DE69839351D1 - Verwendung von bakterien mit arginin-deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen - Google Patents

Verwendung von bakterien mit arginin-deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen

Info

Publication number
DE69839351D1
DE69839351D1 DE69839351T DE69839351T DE69839351D1 DE 69839351 D1 DE69839351 D1 DE 69839351D1 DE 69839351 T DE69839351 T DE 69839351T DE 69839351 T DE69839351 T DE 69839351T DE 69839351 D1 DE69839351 D1 DE 69839351D1
Authority
DE
Germany
Prior art keywords
arginin
apoptosis
inhibiting
bacteria
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839351T
Other languages
English (en)
Other versions
DE69839351T2 (de
Inventor
Simone Claudio De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actial Farmaceutica Ltda
Original Assignee
Actial Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actial Farmaceutica Ltda filed Critical Actial Farmaceutica Ltda
Publication of DE69839351D1 publication Critical patent/DE69839351D1/de
Application granted granted Critical
Publication of DE69839351T2 publication Critical patent/DE69839351T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/24—Lactobacillus brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69839351T 1998-02-20 1998-10-13 Verwendung von bakterien mit arginin-deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen Expired - Lifetime DE69839351T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM980103 1998-02-20
IT98RM000103A IT1298918B1 (it) 1998-02-20 1998-02-20 Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
PCT/IT1998/000275 WO1999042568A1 (en) 1998-02-20 1998-10-13 Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria

Publications (2)

Publication Number Publication Date
DE69839351D1 true DE69839351D1 (de) 2008-05-21
DE69839351T2 DE69839351T2 (de) 2009-06-25

Family

ID=11405583

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839351T Expired - Lifetime DE69839351T2 (de) 1998-02-20 1998-10-13 Verwendung von bakterien mit arginin-deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen

Country Status (25)

Country Link
US (2) US6572854B1 (de)
EP (1) EP1058725B1 (de)
JP (1) JP4253439B2 (de)
KR (1) KR100594569B1 (de)
CN (1) CN1189560C (de)
AR (2) AR020053A1 (de)
AT (1) ATE391774T1 (de)
AU (1) AU754483B2 (de)
BR (1) BR9815677A (de)
CA (1) CA2321263C (de)
CY (1) CY1108112T1 (de)
DE (1) DE69839351T2 (de)
DK (1) DK1058725T3 (de)
EA (1) EA006018B1 (de)
ES (1) ES2303357T3 (de)
HK (1) HK1033338A1 (de)
IL (1) IL137799A (de)
IN (2) IN188450B (de)
IT (1) IT1298918B1 (de)
MX (1) MX237377B (de)
PT (1) PT1058725E (de)
SI (1) SI1058725T1 (de)
TR (1) TR200002326T2 (de)
WO (1) WO1999042568A1 (de)
ZA (1) ZA9811619B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
US8697051B2 (en) * 1999-06-09 2014-04-15 Vsl Pharmaceuticals Inc. Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
IT1311495B1 (it) * 1999-06-09 2002-03-13 Mendes S U R L Composizione comprendente sfingomielinasi alcalina, utilizzabile qualeprodotto dietetico, integratore alimentare o medicamento.
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
HU227086B1 (en) 1999-11-25 2010-06-28 Vakcina Kft Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
US6767537B2 (en) * 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
EP1432426A2 (de) * 2001-09-05 2004-06-30 ACTIAL Farmaceutica Lda. Milchsäurebakterien mit nicht-methylierten cytosin-guanin-dinukleotiden zur therapeutischen verwendung
ITRM20010763A1 (it) 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
EP1599217B1 (de) * 2002-11-18 2014-04-16 Polaris Group Verfahren zur verhinderung von virusreplikation in vivo
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
TW200700074A (en) * 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
KR20090092315A (ko) 2006-12-21 2009-08-31 칼피스가부시키가이샤 ＩｇＡ 생산 촉진제
CN100584940C (zh) * 2007-05-17 2010-01-27 江南大学 一株产精氨酸脱亚氨酶的菌种及其应用
JP5247120B2 (ja) * 2007-11-02 2013-07-24 雪印メグミルク株式会社 Ｌ−オルニチン含有物の製造方法
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN101606952B (zh) * 2008-06-17 2012-09-19 上海交通大学医学院附属第三人民医院 乳双歧杆菌在制备预防泌尿系统结石药物中的应用
JP5526320B2 (ja) * 2008-09-04 2014-06-18 国立大学法人旭川医科大学 腸管保護剤
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN106890198A (zh) * 2009-10-22 2017-06-27 株式会社益力多本社 癌症发病风险降低剂
EP2559437B1 (de) 2010-04-08 2016-05-04 National University Corporation Asahikawa Medical University Intestinales schutzmittel
KR101062779B1 (ko) 2010-04-28 2011-09-06 삼육대학교산학협력단 충치 유발 세균의 성장 억제 활성을 나타내는 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 및 상기 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 또는 이의 배양물을 유효 성분으로 하는 충치 예방용 식품 및 약제학 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN102433290B (zh) * 2012-01-16 2013-06-12 江南大学 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法
ES2828656T3 (es) 2012-04-04 2021-05-27 Polaris Group Composición que comprende arginina desiminasa pegilada
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SG11201605881YA (en) * 2014-01-22 2016-09-29 Meiji Co Ltd Method for preparing citrulline
KR102353046B1 (ko) 2014-03-18 2022-01-19 티디더블유 그룹 조작된 키메라성 페길화된 ａｄｉ 및 사용 방법
EP3193913B1 (de) 2014-09-16 2022-05-11 Polaris Group Arginin-deiminase mit verminderter kreuzreaktivität gegenüber adi-peg-20-antikörpern zur krebsbehandlung
EA035925B1 (ru) 2014-12-23 2020-09-01 4Д Фарма Рисерч Лимитед Полипептид и иммуномодуляция
EP3065748B1 (de) 2014-12-23 2017-11-22 4D Pharma Research Limited Ein bacteroides thetaiotaomicron stamm und seine verwendung zur verminderung von entzündungen
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6439037B2 (ja) 2015-06-15 2018-12-19 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3240554T2 (ro) 2015-06-15 2020-01-31 4D Pharma Res Ltd Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
CA2988693A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
RS57138B1 (sr) 2015-11-20 2018-07-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN106994134B (zh) * 2016-01-25 2020-08-25 深圳华大生命科学研究院 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018067689A2 (pt) 2016-03-04 2019-01-08 4D Pharma Plc composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018125735A1 (en) * 2016-12-29 2018-07-05 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
CN108265068B (zh) * 2016-12-31 2021-06-15 江苏众红生物工程创药研究院有限公司 重组精氨酸脱亚胺酶及其产业化制备方法和应用
MA48941A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3630942B1 (de) 2017-05-24 2022-11-30 4D Pharma Research Limited Zusammensetzungen mit bakterienstamm
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
RS60910B1 (sr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijski soj roda megasphaera i njihove upotrebe
RU2675110C1 (ru) * 2018-04-09 2018-12-17 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция для терапии воспалительных заболеваний слизистых оболочек кишечника на основе штамма Lactobacillus brevis 47f, проявляющая местную противовоспалительную активность
FR3082207B1 (fr) * 2018-06-06 2022-03-25 Agronomique Inst Nat Rech Nouvelle souche probiotique de lactobacillus brevis
KR102069622B1 (ko) * 2019-06-25 2020-01-23 한국식품연구원 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR102363111B1 (ko) * 2021-06-29 2022-02-15 (주)바이오일레븐 항염 및 항산화 활성을 갖는 락토바실러스 퍼멘텀 균주 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415550A (en) * 1983-03-04 1983-11-15 Pakhomov Gennady N Treatment-and-prophylactic tooth paste possessing anticarious effect
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
GB9107305D0 (en) * 1991-04-08 1991-05-22 Unilever Plc Probiotic
AUPM596894A0 (en) 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)

Also Published As

Publication number Publication date
ZA9811619B (en) 1999-06-23
AU754483B2 (en) 2002-11-14
IN1999KO00116A (de) 2005-03-11
CA2321263A1 (en) 1999-08-26
EP1058725B1 (de) 2008-04-09
CY1108112T1 (el) 2014-02-12
ATE391774T1 (de) 2008-04-15
TR200002326T2 (tr) 2000-11-21
KR100594569B1 (ko) 2006-06-30
CN1284994A (zh) 2001-02-21
JP2002504324A (ja) 2002-02-12
MXPA00007990A (es) 2001-03-01
EA006018B1 (ru) 2005-08-25
IL137799A (en) 2005-08-31
AU9644198A (en) 1999-09-06
AR071841A2 (es) 2010-07-21
CA2321263C (en) 2009-08-11
BR9815677A (pt) 2000-10-24
DK1058725T3 (da) 2008-08-18
HK1033338A1 (en) 2001-08-24
CN1189560C (zh) 2005-02-16
KR20010106092A (ko) 2001-11-29
JP4253439B2 (ja) 2009-04-15
US6572854B1 (en) 2003-06-03
ITRM980103A1 (it) 1999-08-20
ITRM980103A0 (it) 1998-02-20
AR020053A1 (es) 2002-04-10
IL137799A0 (en) 2001-10-31
MX237377B (es) 2006-05-31
US20030215429A1 (en) 2003-11-20
WO1999042568A1 (en) 1999-08-26
EA200000856A1 (ru) 2001-02-26
EP1058725A1 (de) 2000-12-13
DE69839351T2 (de) 2009-06-25
IT1298918B1 (it) 2000-02-07
ES2303357T3 (es) 2008-08-01
IN188450B (de) 2002-09-28
SI1058725T1 (sl) 2008-08-31
US7147847B2 (en) 2006-12-12
PT1058725E (pt) 2008-06-19

Similar Documents

Publication Publication Date Title
DE69839351D1 (de) Verwendung von bakterien mit arginin-deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69729646D1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
DE69535166D1 (de) System zur Steuerung der Verteilung und Benutzung von Digitalwerken
DE69535761D1 (de) System zur Steuerung der Verteilung und Benutzung von Digitalwerken
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
ATE288424T1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
DE69937680D1 (de) Agentien zur verbesserung der suesse sowie diese verwendende lebensmittel
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69900249T2 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69030825D1 (de) Katheter zur gleichmässigen Verteilung von therapeutischen Flüssigkeiten
DE3685762D1 (de) 3-aryluracile und deren verwendung zur unkrautbekaempfung.
ATE262892T1 (de) Verwendung einer zusammensetzung enthaltend capsaicin oder resiniferatoxin zur behandlung des reizdarmsyndroms
DE69533847D1 (de) System zur Steuerung der Verteilung und Benutzung von zusammengesetzten Digitalwerken
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE69226725T2 (de) Beschichtungsanlage mittels Kathodenzerstäubung und Methode zur Steuerung derselben
DE3880893D1 (de) Fluessige modifizierte statistische aethylencopolymere und ihre verwendung.
NO990433D0 (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69912670D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69113993D1 (de) Ventil zum transfer und zur dosierung von flüssigkeiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition